CA
NZ
UK
AU
IND
US
● Nano-X Imaging posted 37%Revenuegrowth alongside aGAAPnet loss of $55.5 million driven by a $40.7 millionImpairmentcharge.
Regeneron (NASDAQ:REGN) has built a formidableBusinesson a handful of blockbuster medicines, but its future depends on what comes next. As its older products face growing competition, pipeline progress, turning laboratory science into approved, saleable drugs, is crucial to itsNasdaq100 healthcare story.
● Synergy CHC disclosed aNasdaqnotice on 20 August 2026 for failing to timely file its Form 10-Q for the quarter ended 30 June 2026, with a compliance plan due by 19 October 2026.
Vertex Pharmaceuticals (NASDAQ:VRTX) built a remarkableBusinessby dominating the treatment of a single rare disease, cystic fibrosis. Now the crucial question forNasdaq100 investors is whether it can repeat that success elsewhere, because itsLong-term Growthdepends on expanding beyond theFranchisethat made it, into new areas such as …
Alnylam Pharmaceuticals (NASDAQ:ALNY) pioneered an entirely new class of medicine, drugs that silence disease-causing genes, and it is now turning that science into fast-growing commercial products. As those medicines reach more patients, Alnylam brings the promise of RNA-based therapies into theNasdaq100 growth debate, offering …
Amgen's (NASDAQ:AMGN) next chapter will be written by its pipeline, and one experimental medicine in particular has captured investors' attention: a monthly obesity injection that could let the company compete in one of the fastest-growing markets in healthcare. ForNasdaq100 investors, Amgen is a reminder …
● CalciMedica completed a one-for-fiveReverse Stock Spliteffective 31 August 2026 while reporting FDA alignment on a Phase 2b Auxora trial design and a roughly $49 million private placement.
● Cadrenal Therapeutics reported about $2.3 million in cash at 31 March 2026 and lined up an up-to-$8.8 million privatePlacementto extend its runway toward 2027.
● RVTY shares closed up 9.11% at $140.19, a fresh 52-week high, lifting marketCapitalizationto roughly $15.6 billion.
● The pullback followed a powerful run to record highs rather than any fresh negative development.
Please wait processing your request...